SCHEMBL21373365

SCHEMBL21373365

Cc1cccc(Cl)c1N1C(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2N2CCN=C21

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 14/20 0.59
▸ SIK2 Q9H0K1 1/20 0.56
▸ CYP3A4 P08684 1/20 0.55
▸ KCNH2 Q12809 1/20 0.52
▸ CCNK O75909 2/20 0.51
▸ CCNA2 P20248 2/20 0.51
▸ CDK2 P24941 2/20 0.51
▸ CCND3 P30281 2/20 0.51
▸ CDK9 P50750 2/20 0.51
▸ CDK6 Q00534 2/20 0.51
▸ SRC P12931 2/20 0.50
▸ FGFR1 P11362 1/20 0.50
▸ FGFR2 P21802 1/20 0.50
▸ FGFR4 P22455 1/20 0.50
▸ FGFR3 P22607 1/20 0.50
▸ LCK P06239 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ CDK4 P11802 1/20 0.48
▸ CCND1 P24385 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506532 1.00 WEE1 (0.59) WEE1SIK2CYP3A4KCNH2CCNK
SCHEMBL29506538 0.95 WEE1 (0.62) WEE1SIK2CYP3A4KCNH2SRC
SCHEMBL20180746 0.95 WEE1 (0.62) WEE1SIK2CYP3A4KCNH2SRC
SCHEMBL29506599 0.94 WEE1 (0.54) WEE1SIK2CYP3A4CCNKCCNA2
SCHEMBL5235004 0.94 WEE1 (0.54) WEE1SIK2CYP3A4CCNKCCNA2
SCHEMBL21373346 0.91 WEE1 (0.65) WEE1SIK2CYP3A4KCNH2SRC
SCHEMBL29506474 0.91 WEE1 (0.65) WEE1SIK2CYP3A4KCNH2SRC
SCHEMBL21373382 0.91 WEE1 (0.60) WEE1SIK2KCNH2SRC
SCHEMBL29506441 0.91 WEE1 (0.60) WEE1SIK2KCNH2SRC
SCHEMBL21373322 0.91 WEE1 (0.65) WEE1SIK2CYP3A4KCNH2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240091233-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER Impact Therapeutics (Shanghai), Inc (CN) 2024-03-21 — — US claimed
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 — — EP claimed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 — — US claimed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 — — US claimed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 — — US claimed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 — — US claimed
EP-3543242-A1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND Impact Therapeutics, Inc (CN) 2019-09-25 — — EP claimed
US-20240091233-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER Impact Therapeutics (Shanghai), Inc (CN) 2024-03-21 — — US disclosed
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 — — EP disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 — — US disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 — — US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 — — US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 — — US disclosed
EP-3543242-A1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND Impact Therapeutics, Inc (CN) 2019-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 WEE1 1/4885SIK2 545/4885CYP3A4 2889/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 WEE1 1/4885SIK2 545/4885CYP3A4 2889/4885
US-20240091233-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER WEE1, WEE2, EZH2 WEE1 1/4885SIK2 93/4885CYP3A4 4088/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 WEE1 1/4885SIK2 545/4885CYP3A4 2889/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 WEE1 1/4885SIK2 545/4885CYP3A4 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback